company background image
PYPD logo

PolyPid NasdaqCM:PYPD Stock Report

Last Price

US$3.02

Market Cap

US$20.1m

7D

-9.6%

1Y

-35.7%

Updated

06 Dec, 2024

Data

Company Financials +

PYPD Stock Overview

A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. More details

PYPD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PolyPid Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PolyPid
Historical stock prices
Current Share PriceUS$3.02
52 Week HighUS$9.20
52 Week LowUS$2.90
Beta1.33
11 Month Change-11.70%
3 Month Change-12.21%
1 Year Change-35.74%
33 Year Change-98.54%
5 Year Changen/a
Change since IPO-99.47%

Recent News & Updates

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

PolyPid: Strong Pipeline, Close Catalysts

Apr 19

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Mar 18
Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Nov 08
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Jul 15
We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

Shareholder Returns

PYPDUS PharmaceuticalsUS Market
7D-9.6%0.8%1.0%
1Y-35.7%13.4%32.3%

Return vs Industry: PYPD underperformed the US Pharmaceuticals industry which returned 14% over the past year.

Return vs Market: PYPD underperformed the US Market which returned 32.4% over the past year.

Price Volatility

Is PYPD's price volatile compared to industry and market?
PYPD volatility
PYPD Average Weekly Movement8.4%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: PYPD has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PYPD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200861Dikla Czaczkes Akselbradwww.polypid.com

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer.

PolyPid Ltd. Fundamentals Summary

How do PolyPid's earnings and revenue compare to its market cap?
PYPD fundamental statistics
Market capUS$20.07m
Earnings (TTM)-US$26.86m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYPD income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$26.86m
Earnings-US$26.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.95
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio357.1%

How did PYPD perform over the long term?

See historical performance and comparison